A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab in Combination With Carboplatin and Paclitaxel as First Line Therapy in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Patients with histologically or cytologically confirmed stage IIIB or stage IV
advanced primary non-small cell lung cancinoma

- Age 18 years or older

Exclusion Criteria:

- Received investigational (not yet approved by a regulatory authority) or
non-investigational agent to treat Lung Cancer

- Received radiation therapy within 4 weeks before randomization

- Major surgery within 4 weeks before randomization

- Minor surgery within 2 weeks before randomizaiton

- Systemic steroids within 1 week before randomization

- Any grade 2 or greater neuropathy

- History of severe (Grade 4) hypersensitivity reaction to products containing
Cremophor EL (cyclosporine, teniposide)

- History of any infection requiring hospitalization or antibiotics within 2 weeks
before randomization

- Known brain or spinal cord metastases

- History of other cancers within 5 years before randomization

- Known HIV, hepatitis-B or hepatitis-C infection

- Pregnant or breast-feeding women

- Previously treated with Mapatumumab